IL17A and psoriasis: Although biological agents such as interleukin (IL)-17/IL-23 have made certain achievements in recent years (Blauvelt et al., 2022; Thaçi et al., 2022), the treatment of psoriasis still requires the combination of multiple means, especially the application of external medicines.